Senior Director
embecta
Senior Director
embecta
Manufactures insulin delivery devices worldwide
embecta is a global medical device company with a 100-year legacy in insulin delivery and diabetes care. Driven by innovation, purpose, and a commitment to improving lives, we are expanding our portfolio of solutions to serve even more patients, healthcare providers, and communities around the world.
The Senior Director of Finance Analytics & Insights will envision, design and build the company's enterprise reporting and analytics capability from the ground up. This leader will create a capability that brings together data, systems and best-in-class analytics to become the single source of truth for the company's financial information.
The role will enable self-service reporting for both finance and non-finance business partners and will position Finance to take full advantage of AI and advanced analytics. As the finance product owner for all reporting and analytics development, this leader will partner closely with IT to turn business needs into scalable, governed and trusted solutions.
RESPONSIBILITIES:
Strategy and Vision
Single Source of Truth and Governance
Self-Service Reporting and Analytics
AI, Automation and Advanced Analytics
Finance Product Ownership
Business Partnership
Team Leadership
Experience and Education
Preferred
#LI-DF1
#LI-HYBRID
embecta is an Equal Opportunity/Affirmative Action Employer. We do not unlawfully discriminate on the basis of race, color, religion, age, sex, creed, national origin, ancestry, citizenship status, marital or domestic or civil union status, familial status, affectional or sexual orientation, gender identity or expression, genetics, disability, military eligibility or veteran status, or any other protected status.
Embecta designs, manufactures, and sells insulin delivery devices such as pen needles, insulin syringes, and safety injection devices for diabetes patients around the world. Its products are used to inject insulin and include disposable components like Nano and Ultra-Fine needles, with a tubeless insulin patch pump once pursued but later refocused on core injection devices. The company differentiates itself as a dedicated diabetes injection devices supplier with a global manufacturing footprint and an established distribution network, originating as a BD spin-off. Embecta aims to grow through strategic expansion, including an announced plan to acquire Owen Mumford to broaden into drug-delivery platforms beyond diabetes.
Explore more opportunities at embecta